94 related articles for article (PubMed ID: 7708259)
1. Identification of risk factors on secondary hyperparathyroidism undergoing long-term haemodialysis with vitamin D3.
Mizumoto D; Watanabe Y; Fukuzawa Y; Yuzawa Y; Yamazaki C
Nephrol Dial Transplant; 1994; 9(12):1751-8. PubMed ID: 7708259
[TBL] [Abstract][Full Text] [Related]
2. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
3. [Evaluation of secondary hyperparathyroidism in the patients undergoing hemodialysis--focused on parathyroid hormone assay system].
Watanabe Y; Yuzawa Y; Mizumoto D; Itoh Y; Itoh A; Yamazaki C
Rinsho Byori; 1992 Oct; 40(10):1014-20. PubMed ID: 1339162
[TBL] [Abstract][Full Text] [Related]
4. Controlled trial of falecalcitriol versus alfacalcidol in suppression of parathyroid hormone in hemodialysis patients with secondary hyperparathyroidism.
Akiba T; Marumo F; Owada A; Kurihara S; Inoue A; Chida Y; Ando R; Shinoda T; Ishida Y; Ohashi Y
Am J Kidney Dis; 1998 Aug; 32(2):238-46. PubMed ID: 9708607
[TBL] [Abstract][Full Text] [Related]
5. Control of parathyroid function in patients with a short history of hemodialysis.
Nishi H; Sato T; Kurihara T; Kurosawa T; Fukagawa M
Ther Apher Dial; 2005 Feb; 9(1):39-43. PubMed ID: 15828904
[TBL] [Abstract][Full Text] [Related]
6. Relationship of predialytic intact parathyroid hormone on secondary hyperparathyroidism in chronic maintenance haemodialysis patients.
Etoh S; Murata T; Hasegawa Y; Miyahara Y; Ishimura A; Abe Y; Noda R; Ogahara S; Kaneoka H; Saito T
Nephrology (Carlton); 2004 Jun; 9(3):161-6. PubMed ID: 15189177
[TBL] [Abstract][Full Text] [Related]
7. Low-dose alfacalcidol controls secondary hyperparathyroidism in predialysis chronic kidney disease.
Reichel H
Nephron Clin Pract; 2010; 114(4):c268-76. PubMed ID: 20090369
[TBL] [Abstract][Full Text] [Related]
8. [Prevalence of secondary hyperparathyroidism (SHPT) and causal factors in adult population in Reykjavík area].
Karlsson SL; Indridason OS; Franzson L; Sigurdsson G
Laeknabladid; 2005 Feb; 91(2):161-9. PubMed ID: 16155312
[TBL] [Abstract][Full Text] [Related]
9. Early identification of risk factors for refractory secondary hyperparathyroidism in patients with long-term renal replacement therapy.
Jorna FH; Tobé TJ; Huisman RM; de Jong PE; Plukker JT; Stegeman CA
Nephrol Dial Transplant; 2004 May; 19(5):1168-73. PubMed ID: 14993501
[TBL] [Abstract][Full Text] [Related]
10. [A long-term comparative study of calcitriol versus alphacalcidol in patients with secondary hyperparathyroidism on hemodialysis].
Arenas MD; Muray S; Amoedo ML; Egea JJ; Millán I; Gil MT
Nefrologia; 2006; 26(2):226-33. PubMed ID: 16808261
[TBL] [Abstract][Full Text] [Related]
11. Parathyroid hormone during maintenance dialysis: influence of low calcium dialysate, plasma albumin and age.
Heaf JG; Løkkegård H
J Nephrol; 1998; 11(4):203-10. PubMed ID: 9702872
[TBL] [Abstract][Full Text] [Related]
12. [A trial of suppressing secondary hyperparathyroidism by oral high dose therapy of 1, 25-dihydroxyvitamin D3].
Shigematsu T; Kawaguchi Y; Unemura S; Suzuki M; Yamamoto H; Morita T; Momose M; Ogawa A; Nakayama M; Miyahara T
Nihon Jinzo Gakkai Shi; 1989 Apr; 31(4):393-401. PubMed ID: 2787433
[TBL] [Abstract][Full Text] [Related]
13. Severe secondary hyperparathyroidism in patients on haemodialysis is associated with a high initial serum parathyroid hormone and beta-CrossLaps level: Results from an incident cohort.
Jean G; Lafage-Proust MH; Souberbielle JC; Lechevallier S; Deleaval P; Lorriaux C; Hurot JM; Mayor B; Mehdi M; Chazot C
PLoS One; 2018; 13(6):e0199140. PubMed ID: 29912988
[TBL] [Abstract][Full Text] [Related]
14. Alphacalcidol oral pulses are effective in secondary hyperparathyroidism prior to dialysis.
Koskimies O; Ala-Houhala M
Clin Nephrol; 1996 Jul; 46(1):70-1. PubMed ID: 8832157
[TBL] [Abstract][Full Text] [Related]
15. Comparisons between oral pulse alfacalcidol therapy and daily therapy in maintenance hemodialysis patients with secondary hyperparathyroidism: a randomized, controlled, and multicenter study.
Gu Y; Ding F; Chen N; Mei CL; Qian JQ; Wang XY; Shi W; Hou FF; Li XW; Wang M; Chen YP
Ren Fail; 2005; 27(2):205-12. PubMed ID: 15807187
[TBL] [Abstract][Full Text] [Related]
16. Parathyroidectomy as a therapeutic tool for targeting the recommended NKF-K/DOQI ranges for serum calcium, phosphate and parathyroid hormone in dialysis patients.
Mazzaferro S; Pasquali M; Farcomeni A; Vestri AR; Filippini A; Romani AM; Barresi G; Pugliese F
Nephrol Dial Transplant; 2008 Jul; 23(7):2319-23. PubMed ID: 18281320
[TBL] [Abstract][Full Text] [Related]
17. [How to deal with those low parathyroid hormone values in dialysis patients?].
Jean G; Lafage-Proust MH; Souberbielle JC; Granjon S; Lorriaux C; Hurot JM; Mayor B; Deleaval P; Chazot C
Nephrol Ther; 2012 Nov; 8(6):462-7. PubMed ID: 22627198
[TBL] [Abstract][Full Text] [Related]
18. A randomised clinical study of alfacalcidol and paricalcitol.
Hansen D
Dan Med J; 2012 Feb; 59(2):B4400. PubMed ID: 22293059
[TBL] [Abstract][Full Text] [Related]
19. Beneficial effects of better control of secondary hyperparathyroidism with paricalcitol in chronic dialysis patients.
Capuano A; Serio V; Pota A; Memoli B; Andreucci VE
J Nephrol; 2009; 22(1):59-68. PubMed ID: 19229819
[TBL] [Abstract][Full Text] [Related]
20. Secondary hyperparathyroidism and risk factors in patients undergoing peritoneal dialysis in a tertiary hospital.
Suwan N
J Med Assoc Thai; 2011 Sep; 94 Suppl 4():S101-5. PubMed ID: 22043575
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
